David MacDonald

David MacDonald focuses on intellectual property, pharmaceutical and technology transactions, including joint ventures, consortiums and strategic alliances. He regularly advises pharmaceutical and biotechnology clients on transactional matters, including licensing, marketing and co-promotion, supply and distribution, and other collaboration arrangements. He advises global technology companies on patent strategies, patent and software licensing (including settlement of patent litigation), and monetization (assertion, securitizations, trusts and investment funds). David also advises clients on the intellectual property issues that arise in mergers, acquisitions, divestitures, recapitalizations and bankruptcies. Since 2010, David has been included in Intellectual Asset Management magazine’s list of the world’s top 250 patent and technology licensing lawyers for his “cutting-edge expertise on how patent law issues complicate licensing deals” and his “impressive profile in IT outsourcing.” David has also been included in the IAM Patent 1000 since 2012, which describes him as “one of the pharmaceutical industry’s go-to deal brokers” and says he “manifests a rare faculty for facilitating complex collaborations and transactions between life sciences entities.” David was also highlighted in The Legal 500 United States 2012, 2015, 2017, 2018, 2020, 2021, 2022, 2023 and 2024 guides to leading U.S. law firms for business. David is the former Chair of the Transactions Involving IP Rights Committee of the ABA and named one of Managing Intellectual Property magazine’s “IP Stars,” 2020–2025.

Rutgers School of Law at Newark, J.D., High Honors, 1997; Harvard University, B.A., Classics, 1991.